Dexxon Holdings Ltd.'s Form 4 filing
Roivant Sciences Ltd.ROIV · filed Apr 26, 2022
- Accession no.
- 0001104659-22-049930
- Filed
- Apr 26, 2022, 6:48 AM ET
- Trade date
- Apr 22-25, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $155.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dexxon Holdings Ltd.CIK 0001636684 | 10% Owner |
| Oren DanCIK 0001636701 | 10% Owner |
| Dexcel Pharma Technologies Ltd.CIK 0001720007 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99.
Referenced by the price of 1 transaction in Table I.
- F4
The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 2 transactions in Table I.